NCT05086692 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT05086692
Title	A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1)
Acronym	ABILITY-1
Recruitment	Recruiting
Gender	both
Phase	Phase Ib/II
Variant Requirements	Yes
Sponsors	Medicenna Therapeutics, Inc.
Indications	malignant pleural mesothelioma clear cell renal cell carcinoma urinary bladder cancer skin squamous cell carcinoma gastroesophageal junction adenocarcinoma head and neck squamous cell carcinoma mucosal melanoma triple-receptor negative breast cancer basal cell carcinoma esophageal cancer skin melanoma Advanced Solid Tumor peritoneum cancer Merkel cell carcinoma endometrial carcinoma lung squamous cell carcinoma acral lentiginous melanoma cervical cancer hepatocellular carcinoma fallopian tube cancer stomach cancer ovary epithelial cancer colorectal cancer lung non-squamous non-small cell carcinoma
Therapies	MDNA11 + Pembrolizumab
Age Groups:	adult \| senior
Covered Countries	USA \| IRL \| ESP \| CAN \| AUS

Additional content available in CKB BOOST